Beyond Air logo
Beyond Air XAIR
$ 3.01 2.24%
report update icon

Quarterly report 2027-Q1
added 08-13-2026

Beyond Air Financial Ratios 2026-2011 | XAIR

Brief overview of Beyond Air's valuation multiples

The review covers five available annual periods spanning 2019 to 2025.

The valuation comparison uses P/S 4.2x (median 6.58x), P/B 1.09x (median 1.87x). The current ratio basket stands about 39% below the five-year comparison base. Earnings and risk trends should explain the discount.

Returns on assets and capital are represented by ROE -3.4%, ROA -155.1%, ROCE -3.3%. The business is not generating positive returns on invested resources. Valuation should be read cautiously until earnings recover.

The time from paying for inputs to receiving cash fell from 88.8 days to 72.7 days. Cash turnover improved.

What the ratios show

Beyond Air's discount may reflect genuine profitability issues rather than market inefficiency alone.

Annual Financial Ratios Beyond Air

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-124.8 -0.0 -126.6 -3060.9 -3388.6 -5509.8 -4.3 -6.2 - - - - - - - -

P/S

540.5 0.2 6580.5 - - 144371.8 61.0 5.3 - - - - - - - -

EPS

-4.0 -13.8 -1.8 -1.9 -1.7 -1.3 -1.8 -0.8 -1.7 -3.0 -2.7 - - - - -

EV (Enterprise Value)

4.17 B 11.8 M 7.65 B 171 B 146 B 126 B 74.3 M 44.9 M 7.08 M 9.37 M 24.1 K 4.48 K - - - -

EBITDA per Share

- -12.3 -1.85 -1.72 -1.57 -0.00122 -1.56 -0.352 - - - - - - - -

EV/EBITDA

-160.8 -0.3 -124.9 -3320.1 -3620.4 -5717.2 -3.9 -13.3 - - - - - - - -

PEG

-0.0 -0.0 -0.0 - - - 0.03 0.01 - - - - - - - -

P/B

668.4 0.1 280.5 4065.1 1870.7 4137.3 4.7 10.1 - - - - - - - -

P/CF

-228.8 -0.0 -136.2 -5175.9 -6324.4 -6417.7 -5.5 31.8 - - - - - - - -

ROE %

-542.75 -343.26 -240.51 -147.21 -59.39 -75.09 -110.23 -162.95 - - - - - - - -

ROA %

-93.96 -155.10 -105.76 -81.19 -43.53 -56.45 -72.69 -69.56 - - - - - - - -

ROCE %

-474.11 -327.89 -251.54 -137.30 -55.99 -72.92 -80.41 -75.99 - - - - - - - -

Current Ratio

1.2 1.9 1.9 2.6 4.7 4.0 5.5 1.6 - - - - - - - -

DSO

42.7 50.7 116.4 - - 88.8 32.6 - - - - - - - - -

DIO

93.9 154.5 241.0 486.3 - - - - - - - - - - - -

DPO

107.3 132.5 293.4 1034.2 - - - - - - - - - - - -

Operating Cycle

136.6 205.2 357.3 486.3 - 88.8 - - - - - - - - - -

Cash Conversion Cycle

29.3 72.7 64.0 -547.8 - 88.8 - - - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Beyond Air

2027-Q1 2026-Q4 2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-30.67 - -0.85 -1.25 -1.53 -0.85 -1.25 -1.53 - -2.96 -5.67 -5.32 - -0.5 -0.51 -0.45 - -0.43 -0.4 -0.37 - -0.29 -0.36 -0.67 - -0.33 -0.33 -0.3 -0.4 -0.43 -0.43 -0.38 - 0.11 -0.77 0.53 0.15 -0.28 1.18 0.46 -1.12 - 0.44 0.44 0.58 - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-30.2 - -0.67 -1.08 -1.36 -0.67 -1.08 -1.36 - -2.31 -5.11 -5.61 - -0.51 -0.54 -0.5 - -0.46 -0.42 -0.38 - -0.28 -0.25 -0.55 - -0.31 -0.32 -0.29 -0.4 -0.41 -0.41 -0.4 - -0.28 0.29 -0.28 -0.34 0.39 -0.34 -0.49 0.64 - -0.11 -0.28 -0.42 - - - - - - - - - - - - - - - - - - - -

ROE %

-286.61 -230.28 -320.72 -292.64 -307.75 -301.18 -256.33 -262.91 -185.44 -254.54 -239.90 -230.31 -161.37 -184.37 -134.06 -93.13 -57.12 -66.22 -64.47 -91.81 -76.49 -96.65 -121.07 -135.60 -121.27 -138.07 -141.12 -146.28 -188.71 -248.11 -172.54 -42.48 31.76 0.89 117.95 183.07 1625.85 1731.68 1790.17 1765.23 74.95 - 79.18 79.18 - - - - - - - - - - - - - - - - - - - - -

ROA %

-95.78 -72.95 -92.90 -98.59 -100.30 -111.11 -116.37 -116.96 -89.61 -120.85 -110.65 -104.74 -78.51 -93.09 -73.75 -53.57 -34.28 -34.28 -50.36 -70.71 -58.82 -75.46 -90.91 -98.41 -82.56 -90.50 -93.48 -114.04 -126.17 -162.14 -117.72 -136.45 -105.22 -123.64 -142.30 -335.75 -325.32 -391.79 -1888.87 -3289.87 -84.89 - -1576.27 -1576.27 - - - - - - - - - - - - - - - - - - - - -

ROCE %

-271.33 -218.22 -299.54 -278.38 -294.95 -277.80 -240.29 -256.85 -180.12 -252.39 -253.63 -250.38 -173.65 -198.92 -146.48 -101.69 -61.13 -69.94 -59.82 -78.24 -62.21 -94.84 -120.85 -136.49 -98.24 -134.41 -141.20 -145.81 -192.37 -254.04 -116.71 -29.09 48.26 4.55 74.01 -93.55 -209.19 -267.59 -229.95 -125.57 -102.10 - 9.26 34.72 - - - - - - - - - - - - - - - - - - - - -

Current Ratio

1.2 1.9 1.3 1.7 1.6 1.3 1.7 1.6 1.9 2.2 2.2 1.6 1.9 1.8 2.0 2.1 2.6 - 4.5 4.5 4.7 11.6 4.1 4.1 4.0 3.3 2.9 3.1 2.9 3.5 2.0 2.5 1.7 2.7 0.5 0.8 1.6 0.2 0.4 1.0 1.1 0.1 0.1 0.1 - 0.5 - - - - - - - - - - - - - - - - - - -

DSO

46.6 - 42.5 42.6 50.7 42.5 42.6 39.2 - 50.9 59.0 53.0 - 58.2 47.5 34.0 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DIO

108.7 - 96.1 100.5 119.3 96.1 100.5 138.0 - 173.9 119.2 202.9 - 189.5 307.6 371.6 - 477.1 356.1 264.1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

124.2 - 99.2 68.1 98.0 99.2 68.1 90.8 - 136.4 111.6 227.3 - 397.2 531.2 565.3 - 1345.9 775.9 552.3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

- - - - - 138.6 143.1 177.2 - 224.8 178.2 255.9 - 247.7 355.2 371.6 - 477.1 356.1 264.1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

- - - - - 39.4 75.0 86.4 - 88.4 66.6 28.6 - -149.5 -176.1 -193.6 - -868.9 -419.8 -288.3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Beyond Air, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
AxoGen AxoGen
AXGN
$ 43.32 0.04 % $ 1.99 B usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 59.67 0.18 % $ 9.06 B usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 8.73 1.16 % $ 637 M israelIsrael
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 14.97 13.03 % $ 424 M usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 45.8 3.31 % $ 1.42 B usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 4.91 0.75 % $ 306 M usaUSA
Delcath Systems Delcath Systems
DCTH
$ 15.96 1.8 % $ 572 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 5.7 0.43 % $ 770 M usaUSA
Electromed Electromed
ELMD
$ 27.57 0.11 % $ 228 M usaUSA
Establishment Labs Holdings Establishment Labs Holdings
ESTA
$ 67.76 3.69 % $ 2.01 B costa-ricaCosta-rica
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
EW
$ 86.82 0.51 % $ 50.8 B usaUSA
Align Technology Align Technology
ALGN
$ 148.17 4.36 % $ 10.7 B usaUSA
Helius Medical Technologies Helius Medical Technologies
HSDT
$ 2.88 2.45 % $ 63.5 M usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 15.53 2.76 % $ 1.19 B usaUSA
Inogen Inogen
INGN
$ 5.09 2.55 % $ 135 M usaUSA
Inspire Medical Systems Inspire Medical Systems
INSP
$ 69.06 0.57 % $ 2.03 B usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.63 0.08 % $ 10.7 M usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 86.35 0.08 % $ 1.1 B usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 126.32 0.02 % $ 4.39 B usaUSA
LENSAR LENSAR
LNSR
$ 7.15 0.14 % $ 85.5 M usaUSA
Medigus Ltd. Medigus Ltd.
MDGS
- 10.28 % $ 55.5 M israelIsrael
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 2.95 1.37 % $ 121 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Medtronic PLC Medtronic PLC
MDT
$ 89.3 0.08 % $ 114 B usaUSA
MiMedx Group MiMedx Group
MDXG
$ 4.77 0.2 % $ 705 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.23 1.0 % $ 28.2 M usaUSA
Myomo Myomo
MYO
$ 1.64 0.3 % $ 68.6 M usaUSA
Nano-X Imaging Ltd. Nano-X Imaging Ltd.
NNOX
$ 0.7 0.45 % $ 45.4 M israelIsrael
Nemaura Medical Nemaura Medical
NMRD
- -17.8 % $ 2.74 M britainBritain
InspireMD InspireMD
NSPR
$ 0.74 0.16 % $ 47.6 M israelIsrael
Orthofix Medical Orthofix Medical
OFIX
$ 9.18 2.23 % $ 364 M curacaoCuracao
Outset Medical Outset Medical
OM
$ 3.09 5.45 % $ 47 K usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 44.62 0.31 % $ 66.1 B usaUSA
Insulet Corporation Insulet Corporation
PODD
$ 136.49 0.01 % $ 9.6 B usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 5.74 0.16 % $ 174 M canadaCanada
Quanterix Corporation Quanterix Corporation
QTRX
$ 3.16 4.93 % $ 135 M usaUSA
AVITA Medical AVITA Medical
RCEL
$ 10.95 0.61 % $ 305 M australiaAustralia
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Sintx Technologies Sintx Technologies
SINT
$ 1.78 3.98 % $ 4.94 M usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 26.82 0.07 % $ 23.3 B britainBritain
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA
Sensus Healthcare Sensus Healthcare
SRTS
$ 3.03 0.32 % $ 49.5 M usaUSA
Stryker Corporation Stryker Corporation
SYK
$ 273.4 0.38 % $ 104 B usaUSA
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 22.43 0.55 % $ 513 M usaUSA
TELA Bio TELA Bio
TELA
$ 1.3 0.71 % $ 61 M usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 8.8 1.24 % $ 342 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
$ 18.45 0.05 % $ 764 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA